Trinity Biotech Plc ADR Dossier - Source-backed chat

Trinity Biotech Plc ADR

TRIBNASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)1.01

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $6.43Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $5.2M

Enterprise Value $271.4K

Shares Outstanding 813.1K diluted

Last ex-dividend5 Jun 2015

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Trinity Biotech is undergoing a Comprehensive Transformation Plan focused on offshoring and outsourcing its rapid HIV test manufacturing (UniGold) and commercializing its next-generation CGM+ biosensor platform. While Q1 2026 results showed a strong recovery with revenue up 43% YoY to $10.8M and gross margins expanding to 35.4%, the company faces severe liquidity risks, high leverage ($141.3M total debt), and ongoing Nasdaq compliance challenges. A 'Hold' is recommended until the outsourced manufacturing model is fully scaled in Q3 2026 and the capital structure stabilizes.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Delays in the outsourced manufacturing transition cause severe quarter-on-quarter revenue volatility and inventory write-downs. The company fails to regain Nasdaq compliance by August 2026, leading to delisting, and high debt service costs force highly dilutive equity issuances under the YA II PN Standby Equity Purchase Agreement.

Base CaseCentral scenario

The company successfully completes its transition to outsourced manufacturing for UniGold HIV tests in Q3 2026, leading to sustained gross margin expansion above 40% and narrowing net losses. The CGM+ platform advances through pivotal trials, and the company maintains its Nasdaq listing through strategic capital adjustments.

Bull CaseUpside scenario

Trinity Biotech's transition to an asset-light, outsourced manufacturing model under its Comprehensive Transformation Plan is driving significant gross margin expansion (improving to 35.4% in Q1 2026). The commercialization of its wearable CGM+ biosensor platform and the rollout of maternal health diagnostics like PrePsia through its NYSDOH-certified Immco reference laboratory provide high-growth, high-margin recurring revenue opportunities.

Scenarios reflect our research view at the research date.

Key Investment Merits

Strong commercial momentum for TrinScreen HIV tests with over 2 million units ordered for Q3 2026 delivery.
Significant gross margin expansion (up to 35.4% in Q1 2026 from 25.2% in Q1 2025) driven by the Comprehensive Transformation Plan.
High-growth potential in the wearable biosensor market through the development of the CGM+ platform.

Key Investment Risks

Severe liquidity and leverage risks with total debt of $141.3 million and negative operating cash flows.
Potential massive dilution (up to 829% of outstanding shares) if all convertible debt instruments are exercised.
Nasdaq delisting risk if minimum bid price and market value requirements are not met by August 2026.

Thesis Invalidation Triggers

Failure to complete the commercial scale-up of outsourced UniGold manufacturing by the end of Q3 2026.
Delisting from the Nasdaq Global Select Market.
Inability to secure the $15M-$25M capex required for CGM+ development in 2026, halting clinical trials.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.